#

Dailypharm Live Search Close
  • The government signed an additional 40 million doses
  • by Kim, Jung-Ju | translator Choi HeeYoung | 2021-04-28 06:05:01
Securing twice the amount of the nationwide

The government has signed an additional 40 million doses of Pfizer's COVID-19 vaccine product.

 

As a result, Korea has secured twice the amount of vaccine vaccination in the country, enabling it to achieve the goal of forming collective immunity in November.

 

Pan-government vaccine introduction TF (Team Leader Kwon Deok-cheol, Minister of Health and Welfare) announced that an additional purchase contract for 40 million Pfizer COVID-19 vaccines (for 20 million people) was signed by holding an emergency briefing during the day on the 24th.

 

The government explained that after forming a pan-government vaccine introduction TF to stably supply COVID-19 vaccine on the 1st, it has mobilized all of its government-wide capabilities, including diplomatic efforts, by consistently meeting with each vaccine pharmaceutical company.

 

This contract is the result of ongoing negotiations by discussing the supply of vaccines through video conferences with Pfizer with Kwon Deok-cheol, head of the Pan-Government Vaccine Introduction Task Force on the 9th and 23rd of this month.

 

◆Signed an additional purchase contract for Pfizer vaccine= This year, a total of 66 million doses of Pfizer vaccine, which was originally 26 million doses and 40 million doses contracted, were supplied, resulting in a total of 33 million Pfizer vaccines.

 

Pfizer's vaccine has been supplied in 1.75 million doses so far, including 7 million doses by the end of June, and plans to supply 59 million doses sequentially from the third quarter.

 

Pfizer vaccines have been supplied regularly every week since the start of supply on March 24th.

 

With the signing of an additional purchase contract this time, the foundation for a more stable supply of COVID-19 vaccine has been laid.

 

◆COVID-19 Vaccine Supply Status and Plan The total number of COVID-19 vaccines secured by Korea this year amounted to 192 million doses, a total of 99 million.

 

This is the amount that can be vaccinated for about 1.9 times of the total population in Korea and 2.75 times for the 36 million vaccination targets for the formation of collective immunity.

 

The vaccine contracted for this year was for 79 million people, enough to secure collective immunity, but additional purchases laid the foundation to accelerate the time to achieve collective immunity.

 

It is possible to prepare for additional demands that may arise in the future, such as the 3rd vaccination (called booster shot) to cope with the mutant virus and the expansion of the target age for vaccinations under the age of 18 to prepare for the uncertainty in the international vaccine supply and demand.

 

First of all, the government plans to do its best to achieve the target inoculation for 12 million people with the 18.09 million doses confirmed by the end of June.

 

AstraZeneca and Pfizer vaccines, which are currently being vaccinated, have already supplied 3.87 million doses of vaccine, and a total of 18.09 million doses will be supplied by the second quarter.

 

The government plans to closely monitor the vaccine supply situation on a full-cycle basis to ensure that 18.09 million doses will be supplied without disruption, while additionally introducing some of the Novavax, Moderna and Janssen vaccines within the first half of the year, so that up to 20.8 million doses can be supplied.

 

The government said, "By the end of June, 12 million people are vaccinated to prevent infection in high-risk groups such as nursing hospitals, facility admissions, and residents, thereby preventing severe and death, and through vaccinations for COVID-19 treatment, response personnel, and health care workers.

 

We expected to be able to contribute to the maintenance of the quarantine system." From July, AstraZeneca and Pfizer, as well as Novavax, Moderna, and Janssen vaccines are expected to be supplied in earnest.

 

Accordingly, a total of 100 million vaccines are planned to be supplied by the end of September.

 

The total amount negotiated by the end of September is about 80 million doses of AZ, Pfizer, Novavax, Moderna, and Janssen, and when added to the supply in the first half, about 100 million doses of vaccine will be supplied by the end of September.

 

This is an amount that can be vaccinated to more than 50 million people, and if the supply is smooth, it will be possible to inoculate all 44 million people over the age of 18 with only the amount until the end of September.

 

In order to form collective immunity, vaccination of about 36 million people, or 70% of 52 million people, is necessary.

 

The government said, "Through this additional purchase contract, it is possible to secure a sufficient amount of vaccine and achieve early achievement even after meeting the goal of forming population immunity in November." This is the result of specifying the supply schedule of vaccines, which were scheduled to be supplied in the second half of the year, by pursuing additional contracts through the pan-government vaccine introduction TF and expanding the volume of existing contracted vaccines in the third quarter.

 

Although the supply and demand of vaccines worldwide is uncertain, the government said that through additional purchase contracts and quarterly consultations on supply, the government laid the foundation for more stable and rapid vaccination.

 

About 90 million doses to be supplied in the fourth quarter will be used to respond to a variety of situations in a relaxed manner, and to actively utilize additional vaccinations if necessary.

 

The government said, "In the future, we plan to actively cope with various situations that may arise during the vaccine supply and demand process through comprehensive support such as approval of COVID-19 vaccine, release of national lots, and supply of raw and subsidiary materials.

 

By the end of June, 12 million people will be vaccinated and all government-wide capabilities will be mobilized to achieve collective immunity in November." Minister Kwon Deok-cheol said, "The government will do its best to prevent quarantine, introduce vaccines, and vaccinations so that the people's precious daily lives can be restored.

 

I sincerely ask the people to believe in and actively cooperate with the government's plans and guidance for securing vaccines and vaccinations." The government plans to continue meticulous efforts on vaccine safety.

 

The KCDA Commissioner Jeong Eun-kyeong said, "The vaccines contracted by our government are products that have been approved for safety, and the benefits of vaccination outweigh the risks.

 

I hope you will actively participate in the order of vaccination."

 

  • 0
Reader Comment
0
Member comment Write Operate Rule
Colse

댓글 운영방식은

댓글은 실명게재와 익명게재 방식이 있으며, 실명은 이름과 아이디가 노출됩니다. 익명은 필명으로 등록 가능하며, 대댓글은 익명으로 등록 가능합니다.

댓글 노출방식은

댓글 명예자문위원(팜-코니언-필기모양 아이콘)으로 위촉된 데일리팜 회원의 댓글은 ‘게시판형 보기’와 ’펼쳐보기형’ 리스트에서 항상 최상단에 노출됩니다. 새로운 댓글을 올리는 일반회원은 ‘게시판형’과 ‘펼쳐보기형’ 모두 팜코니언 회원이 쓴 댓글의 하단에 실시간 노출됩니다.

댓글의 삭제 기준은

다음의 경우 사전 통보없이 삭제하고 아이디 이용정지 또는 영구 가입제한이 될 수도 있습니다.

  • 저작권·인격권 등 타인의 권리를 침해하는 경우

    상용 프로그램의 등록과 게재, 배포를 안내하는 게시물

    타인 또는 제3자의 저작권 및 기타 권리를 침해한 내용을 담은 게시물

  • 근거 없는 비방·명예를 훼손하는 게시물

    특정 이용자 및 개인에 대한 인신 공격적인 내용의 글 및 직접적인 욕설이 사용된 경우

    특정 지역 및 종교간의 감정대립을 조장하는 내용

    사실 확인이 안된 소문을 유포 시키는 경우

    욕설과 비어, 속어를 담은 내용

    정당법 및 공직선거법, 관계 법령에 저촉되는 경우(선관위 요청 시 즉시 삭제)

    특정 지역이나 단체를 비하하는 경우

    특정인의 명예를 훼손하여 해당인이 삭제를 요청하는 경우

    특정인의 개인정보(주민등록번호, 전화, 상세주소 등)를 무단으로 게시하는 경우

    타인의 ID 혹은 닉네임을 도용하는 경우

  • 게시판 특성상 제한되는 내용

    서비스 주제와 맞지 않는 내용의 글을 게재한 경우

    동일 내용의 연속 게재 및 여러 기사에 중복 게재한 경우

    부분적으로 변경하여 반복 게재하는 경우도 포함

    제목과 관련 없는 내용의 게시물, 제목과 본문이 무관한 경우

    돈벌기 및 직·간접 상업적 목적의 내용이 포함된 게시물

    게시물 읽기 유도 등을 위해 내용과 무관한 제목을 사용한 경우

  • 수사기관 등의 공식적인 요청이 있는 경우

  • 기타사항

    각 서비스의 필요성에 따라 미리 공지한 경우

    기타 법률에 저촉되는 정보 게재를 목적으로 할 경우

    기타 원만한 운영을 위해 운영자가 필요하다고 판단되는 내용

  • 사실 관계 확인 후 삭제

    저작권자로부터 허락받지 않은 내용을 무단 게재, 복제, 배포하는 경우

    타인의 초상권을 침해하거나 개인정보를 유출하는 경우

    당사에 제공한 이용자의 정보가 허위인 경우 (타인의 ID, 비밀번호 도용 등)

  • ※이상의 내용중 일부 사항에 적용될 경우 이용약관 및 관련 법률에 의해 제재를 받으실 수도 있으며, 민·형사상 처벌을 받을 수도 있습니다.

    ※위에 명시되지 않은 내용이더라도 불법적인 내용으로 판단되거나 데일리팜 서비스에 바람직하지 않다고 판단되는 경우는 선 조치 이후 본 관리 기준을 수정 공시하겠습니다.

    ※기타 문의 사항은 데일리팜 운영자에게 연락주십시오. 메일 주소는 dailypharm@dailypharm.com입니다.

If you want to see the full article, please JOIN US (click)